一种移动IPv6安全绑定更新的新机制

基于扩展的三方Diffie-Hellman算法,提出了移动节点、通信节点和家乡代理三者之间分配共享密钥以解决移动IPv6在优化三角路由的过程中所要求的安全绑定更新问题的新机制,命名为DH-3机制;设计出了DH-3的整个安全绑定更新过程;并对DH-3机制和此领域最有效的CAM-DH机制从安全性以及移动节点计算要求的角度作了比较和分析。DH-3机制不仅提高了移动IPv6安全性,而且突破了CAM—DH机制对移动节点计算能力要求过高的局限,很好地解决了移动Ipv6环境下的安全绑定更新问题。     

基于IXP2400网络处理器的高性能 IPv4/IPv6互通网关

提出了一种基因IXP2400网络处理器的高性能IPv4／IPv6互通网关设计方案,阐述了NAT-PT转换机制中协议地址翻译、映射表管理和应用层网关技术的实现方法,研究了网络处理器环境下硬件资源分配,内部通信机制等问题。性能测试结果验证了设计方案的有效。     

基于ND的中间人攻击及其对策

在分析邻居发现协议运行机制的基础上,指出了链路可信这个默认前提是导致ND(Neighbor Discovery)存在安全缺陷的根本原因,分析了利用ND安全缺陷对链路内的节点进行中间人攻击的方法,并对ND的安全防护进行阐述。测试结果表明,提出的方法是可行的、有效的,大大降低了攻击的影响。     

转发控制分离的IPv6路由器控制体系结构研究

路由器体系结构是决定路由器性能和功能的主导因素。一方面,路由器的功能需求越来越复杂;另一方面,为了满足转发性能需求,普遍采用硬件进行转发。为此,转发控制分离成为一种全新的路由器体系结构。本文在研究分析转发控制分离体系结构的基础上,提出了一种针对IPv6的转发控制分离路由器控制体系结构,并重点研究了转发与控制制分离后所带来的问题,最后设计和实现了一个原型系统。     

基于IPv6智能节点的弹性重叠网络中间件

结合IPv6和P2P技术,提出了基于IPv6的智能节点弹性重叠网络中间件的设计方案,定义了该中间件系统的功能,给出了系统框架结构,讨论了智能节点的功能和扩展机制,设计和实现了节点发现机制。     

IPv4/IPv6双栈防火墙的设计与实现

IPv6的新特点和应用对现有的安全设备结构提出了挑战。同时,从IPv4升级到IPv6是一个长期的过程,两种协议在一定时间内将共同存在。因此,需要设计支持IPv4、IPv6双协议的防火墙以适应过渡时期的需要和IPv6新特点对防火墙的要求。论述了IPv4／IPv6防火墙的设计需要考虑的防火墙位置、IPv6与IPv4的差异及性能,然后介绍防火墙实现的步骤和将要进行的工作。     

基于虚拟骨干网的MANET地址自动配置方法

针对MANET的地址自动配置问题,提出了基于虚拟骨干网的IPv6地址自动配置方法。充分利用了虚拟骨干网的分层结构、骨干网和子网分别执行不同的配置算法,消息复杂度和时间复杂度低,非常适合通信资源宝贵的MANET。     

The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection,Regeneration, and Failure

Oncostatin M (OSM), a member of the interleukin-6 family, functions as a major mediator of cardiomyocyte remodeling under pathological conditions. Its involvement in a variety of human cardiac diseases such as aortic stenosis, myocardial infarction, myocarditis, cardiac sarcoidosis, and various cardiomyopathies make the OSM receptor (OSMR) signaling cascades a promising therapeutic target. However, the development of pharmacological treatment strategies is highly challenging for many reasons. In mouse models of heart disease, OSM elicits opposing effects via activation of the type II receptor complex (OSMR/gp130). Short-term activation of OSMR/gp130 protects the heart after acute injury, whereas chronic activation promotes the development of heart failure. Furthermore, OSM has the ability to integrate signals from unrelated receptors that enhance fetal remodeling (dedifferentiation) of adult cardiomyocytes. Because OSM strongly stimulates the production and secretion of extracellular proteins, it is likely to exert systemic effects, which in turn, could influence cardiac remodeling. Compared with the mouse, the complexity of OSM signaling is even greater in humans because this cytokine also activates the type I leukemia inhibitory factor receptor complex (LIFR/gp130). In this article, we provide an overview of OSM-induced cardiomyocyte remodeling and discuss the consequences of OSMR/gp130 and LIFR/gp130 activation under acute and chronic conditions.     

IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment

The IL-6 cytokine family is a group of signaling molecules with wide expression and function across vertebrates. Each member of the family signals by binding to its specific receptor and at least one molecule of gp130, which is the common transmembrane receptor subunit for the whole group. Signal transduction upon stimulation of the receptor complex results in the activation of multiple downstream cascades, among which, in mammary cells, the JAK-STAT3 pathway plays a central role. In this review, we summarize the role of the IL-6 cytokine family—specifically IL-6 itself, LIF, OSM, and IL-11—as relevant players during breast cancer progression. We have compiled evidence indicating that this group of soluble factors may be used for early and more precise breast cancer diagnosis and to design targeted therapy to treat or even prevent metastasis development, particularly to the bone. Expression profiles and possible therapeutic use of their specific receptors in the different breast cancer subtypes are also described. In addition, participation of these cytokines in pathologies of the breast linked to lactation and involution of the gland, as post-partum breast cancer and mastitis, is discussed.